INOSIM Joins the Drug Delivery Innovation Center

Drug delivery comprises the process by which pharmaceuticals are transported to the human body to achieve a therapeutic effect. For this, an appropriate drug formulation and downstream processing is essential. To foster research and innovation in this area, three pharmaceutical companies (Bayer AG, Merck KGaA and UCB S.A) and LB Bohle GmbH as equipment manufacturer founded the DDIC (Drug Delivery Innovation Center) in 2017 as tier-1 members jointly with the university partners TU Dortmund and HHU Düsseldorf. The DDIC is an open research consortium led by INVITE GmbH in Leverkusen, Germany.

Promoting advances in pharmaceutical scienes

DDIC will foster international, multi-disciplinary, and pre-competitive networks in the area of research to advance in pharmaceutical science in close collaboration with academia and pharmaceutical industry along the value chain. They also focus on increased fundamental process understanding as the foundation of advanced process control, modelling, and prediction. Current research areas include, e.g., continuous processing, process analytical technologies and scalability, drug delivery formulation technologies, biopharmaceutical properties prediction via mathematical models, personalized medicine, and nanomedicine. In addition to research, the DDIC also focuses on training by generating a talent pool for the members – DDIC supports the new Master program of Industrial Pharmacy at the HHU Düsseldorf and a unique PhD training program.

Delivering state-of-the-art simulation software

INOSIM has joined the DDIC as a tier-2 partner in February 2019 to provide the DDIC consortium with our state-of-the-art software tools for process simulation and to contribute our experience in production scale-up and process optimization. Christian Sonntag, Head Of Innovation at INOSIM, is looking forward to this new cooperation: “The DDIC is an exciting new initiative that will push the boundaries in key areas of pharmaceutical science and that will foster new opportunities to transfer cutting-edge developments into pharmaceutical production. INOSIM is looking forward to broadening its knowledge base and its international network of collaboration partners and to contribute its technology and experience to this endeavor.”

Do you have any questions or would like to know more about this topic? Please contact us.